General Information:

Id: 3,794 (click here to show other Interactions for entry)
Diseases: Diabetes mellitus, type II - [OMIM]
Insulin resistance
Rattus norvegicus
male
Zucker fatty (fa/fa) and lean (fa/+) rats
article
Reference: Hsiao G et al.(2011) Multi-tissue, selective PPARgamma modulation of insulin sensitivity and metabolic pathways in obese rats Am. J. Physiol. Endocrinol. Metab. 300: E164-E174 [PMID: 20959535]

Interaction Information:

Comment PPARgamma ligand treatment of the obese rats induced the differential expression of 732 genes in adipose tissue. Genes downregulated by ligand treatment included immune cell markers (Cd68 and Cd74) and genes involved in macrophage transendothelial infiltration (chemokines Ccl6, Cxcl1, Cxcl12, Cxcl14, and Spp1 aka Opn), cell adhesion (Cd24, Cd44, Icam1, Lsp1), and matrix remodeling (Mmp2). Overexpression of nearly all (43/47) of the immune-related genes in FC rats was decreased in the ligand-treated rats. Of these 43 genes, 36 were normalized to LC group levels.
Formal Description
Interaction-ID: 37492

drug/chemical compound

Thiazolidinedione

decreases_expression of

gene/protein

CD68

in adipose tissue; in obese Zucker rats
Comment PPARgamma ligand treatment of the obese rats induced the differential expression of 732 genes in adipose tissue. Genes downregulated by ligand treatment included immune cell markers (Cd68 and Cd74) and genes involved in macrophage transendothelial infiltration (chemokines Ccl6, Cxcl1, Cxcl12, Cxcl14, and Spp1 aka Opn), cell adhesion (Cd24, Cd44, Icam1, Lsp1), and matrix remodeling (Mmp2). Overexpression of nearly all (43/47) of the immune-related genes in FC rats was decreased in the ligand-treated rats. Of these 43 genes, 36 were normalized to LC group levels.
Formal Description
Interaction-ID: 37493

drug/chemical compound

Thiazolidinedione

decreases_expression of

gene/protein

CD74

in adipose tissue; in obese Zucker rats
Comment PPARgamma ligand treatment of the obese rats induced the differential expression of 732 genes in adipose tissue. Genes downregulated by ligand treatment included immune cell markers (Cd68 and Cd74) and genes involved in macrophage transendothelial infiltration (chemokines Ccl6, Cxcl1, Cxcl12, Cxcl14, and Spp1 aka Opn), cell adhesion (Cd24, Cd44, Icam1, Lsp1), and matrix remodeling (Mmp2). Overexpression of nearly all (43/47) of the immune-related genes in FC rats was decreased in the ligand-treated rats. Of these 43 genes, 36 were normalized to LC group levels.
Formal Description
Interaction-ID: 37494

drug/chemical compound

Thiazolidinedione

decreases_expression of

gene/protein

CCL6

in adipose tissue; in obese Zucker rats
Comment PPARgamma ligand treatment of the obese rats induced the differential expression of 732 genes in adipose tissue. Genes downregulated by ligand treatment included immune cell markers (Cd68 and Cd74) and genes involved in macrophage transendothelial infiltration (chemokines Ccl6, Cxcl1, Cxcl12, Cxcl14, and Spp1 aka Opn), cell adhesion (Cd24, Cd44, Icam1, Lsp1), and matrix remodeling (Mmp2). Overexpression of nearly all (43/47) of the immune-related genes in FC rats was decreased in the ligand-treated rats. Of these 43 genes, 36 were normalized to LC group levels.
Formal Description
Interaction-ID: 37495

drug/chemical compound

Thiazolidinedione

decreases_expression of

gene/protein

CXCL1

in adipose tissue; in obese Zucker rats
Comment PPARgamma ligand treatment of the obese rats induced the differential expression of 732 genes in adipose tissue. Genes downregulated by ligand treatment included immune cell markers (Cd68 and Cd74) and genes involved in macrophage transendothelial infiltration (chemokines Ccl6, Cxcl1, Cxcl12, Cxcl14, and Spp1 aka Opn), cell adhesion (Cd24, Cd44, Icam1, Lsp1), and matrix remodeling (Mmp2). Overexpression of nearly all (43/47) of the immune-related genes in FC rats was decreased in the ligand-treated rats. Of these 43 genes, 36 were normalized to LC group levels.
Formal Description
Interaction-ID: 37496

drug/chemical compound

Thiazolidinedione

decreases_expression of

gene/protein

CXCL12

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for CXCL12
Comment PPARgamma ligand treatment of the obese rats induced the differential expression of 732 genes in adipose tissue. Genes downregulated by ligand treatment included immune cell markers (Cd68 and Cd74) and genes involved in macrophage transendothelial infiltration (chemokines Ccl6, Cxcl1, Cxcl12, Cxcl14, and Spp1 aka Opn), cell adhesion (Cd24, Cd44, Icam1, Lsp1), and matrix remodeling (Mmp2). Overexpression of nearly all (43/47) of the immune-related genes in FC rats was decreased in the ligand-treated rats. Of these 43 genes, 36 were normalized to LC group levels.
Formal Description
Interaction-ID: 37497

drug/chemical compound

Thiazolidinedione

decreases_expression of

gene/protein

CXCL14

in adipose tissue; in obese Zucker rats
Comment PPARgamma ligand treatment of the obese rats induced the differential expression of 732 genes in adipose tissue. Genes downregulated by ligand treatment included immune cell markers (Cd68 and Cd74) and genes involved in macrophage transendothelial infiltration (chemokines Ccl6, Cxcl1, Cxcl12, Cxcl14, and Spp1 aka Opn), cell adhesion (Cd24, Cd44, Icam1, Lsp1), and matrix remodeling (Mmp2). Overexpression of nearly all (43/47) of the immune-related genes in FC rats was decreased in the ligand-treated rats. Of these 43 genes, 36 were normalized to LC group levels.
Formal Description
Interaction-ID: 37498

drug/chemical compound

Thiazolidinedione

decreases_expression of

gene/protein

SPP1

in adipose tissue; in obese Zucker rats
Comment PPARgamma ligand treatment of the obese rats induced the differential expression of 732 genes in adipose tissue. Genes downregulated by ligand treatment included immune cell markers (Cd68 and Cd74) and genes involved in macrophage transendothelial infiltration (chemokines Ccl6, Cxcl1, Cxcl12, Cxcl14, and Spp1 aka Opn), cell adhesion (Cd24, Cd44, Icam1, Lsp1), and matrix remodeling (Mmp2). Overexpression of nearly all (43/47) of the immune-related genes in FC rats was decreased in the ligand-treated rats. Of these 43 genes, 36 were normalized to LC group levels.
Formal Description
Interaction-ID: 37499

drug/chemical compound

Thiazolidinedione

decreases_expression of

gene/protein

CD24

in adipose tissue; in obese Zucker rats
Comment PPARgamma ligand treatment of the obese rats induced the differential expression of 732 genes in adipose tissue. Genes downregulated by ligand treatment included immune cell markers (Cd68 and Cd74) and genes involved in macrophage transendothelial infiltration (chemokines Ccl6, Cxcl1, Cxcl12, Cxcl14, and Spp1 aka Opn), cell adhesion (Cd24, Cd44, Icam1, Lsp1), and matrix remodeling (Mmp2). Overexpression of nearly all (43/47) of the immune-related genes in FC rats was decreased in the ligand-treated rats. Of these 43 genes, 36 were normalized to LC group levels.
Formal Description
Interaction-ID: 37500

drug/chemical compound

Thiazolidinedione

decreases_expression of

gene/protein

CD44

in adipose tissue; in obese Zucker rats
Comment PPARgamma ligand treatment of the obese rats induced the differential expression of 732 genes in adipose tissue. Genes downregulated by ligand treatment included immune cell markers (Cd68 and Cd74) and genes involved in macrophage transendothelial infiltration (chemokines Ccl6, Cxcl1, Cxcl12, Cxcl14, and Spp1 aka Opn), cell adhesion (Cd24, Cd44, Icam1, Lsp1), and matrix remodeling (Mmp2). Overexpression of nearly all (43/47) of the immune-related genes in FC rats was decreased in the ligand-treated rats. Of these 43 genes, 36 were normalized to LC group levels.
Formal Description
Interaction-ID: 37501

drug/chemical compound

Thiazolidinedione

decreases_expression of

gene/protein

ICAM1

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for ICAM1
Comment PPARgamma ligand treatment of the obese rats induced the differential expression of 732 genes in adipose tissue. Genes downregulated by ligand treatment included immune cell markers (Cd68 and Cd74) and genes involved in macrophage transendothelial infiltration (chemokines Ccl6, Cxcl1, Cxcl12, Cxcl14, and Spp1 aka Opn), cell adhesion (Cd24, Cd44, Icam1, Lsp1), and matrix remodeling (Mmp2). Overexpression of nearly all (43/47) of the immune-related genes in FC rats was decreased in the ligand-treated rats. Of these 43 genes, 36 were normalized to LC group levels.
Formal Description
Interaction-ID: 37502

drug/chemical compound

Thiazolidinedione

decreases_expression of

gene/protein

LSP1

in adipose tissue; in obese Zucker rats
Comment PPARgamma ligand treatment of the obese rats induced the differential expression of 732 genes in adipose tissue. Genes downregulated by ligand treatment included immune cell markers (Cd68 and Cd74) and genes involved in macrophage transendothelial infiltration (chemokines Ccl6, Cxcl1, Cxcl12, Cxcl14, and Spp1 aka Opn), cell adhesion (Cd24, Cd44, Icam1, Lsp1), and matrix remodeling (Mmp2). Overexpression of nearly all (43/47) of the immune-related genes in FC rats was decreased in the ligand-treated rats. Of these 43 genes, 36 were normalized to LC group levels.
Formal Description
Interaction-ID: 37503

drug/chemical compound

Thiazolidinedione

decreases_expression of

gene/protein

MMP2

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for MMP2
Comment More than 700 genes were selectively modulated by the individual ligand treatments, meaning that their transcriptional responses were significantly different for the different ligand treatments. Functional analysis of this gene set revealed enrichment of many inflammation-related terms including the KEGG pathway term 'cell adhesion molecules' and the ontology term 'immune system process', showing that the PPARgamma ligand treatments modulated these bio-chemical pathways to varying degrees.
Formal Description
Interaction-ID: 37504

drug/chemical compound

Thiazolidinedione

affects_activity of

process

cell adhesion

in adipose tissue
Comment More than 700 genes were selectively modulated by the individual ligand treatments, meaning that their transcriptional responses were significantly different for the different ligand treatments. Functional analysis of this gene set revealed enrichment of many inflammation-related terms including the KEGG pathway term 'cell adhesion molecules' and the ontology term 'immune system process', showing that the PPARgamma ligand treatments modulated these bio-chemical pathways to varying degrees.
Formal Description
Interaction-ID: 37511

drug/chemical compound

Thiazolidinedione

affects_activity of

in adipose tissue
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'oxidative phosphorylation' (OXPHOS), represented by 33 upregulated electron transport chain genes.
Formal Description
Interaction-ID: 37516

drug/chemical compound

Thiazolidinedione

affects_activity of

in adipose tissue
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'oxidative phosphorylation' (OXPHOS), represented by 33 upregulated electron transport chain genes.
Formal Description
Interaction-ID: 37517

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

NDUFS1

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for NDUFS1
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'oxidative phosphorylation' (OXPHOS), represented by 33 upregulated electron transport chain genes.
Formal Description
Interaction-ID: 37518

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

NDUFS2

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for NDUFS2
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'oxidative phosphorylation' (OXPHOS), represented by 33 upregulated electron transport chain genes.
Formal Description
Interaction-ID: 37520

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

NDUFS3

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for NDUFS3
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'oxidative phosphorylation' (OXPHOS), represented by 33 upregulated electron transport chain genes.
Formal Description
Interaction-ID: 37521

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

NDUFS7

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for NDUFS7
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'oxidative phosphorylation' (OXPHOS), represented by 33 upregulated electron transport chain genes.
Formal Description
Interaction-ID: 37522

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

NDUFV1

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for NDUFV1
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'oxidative phosphorylation' (OXPHOS), represented by 33 upregulated electron transport chain genes.
Formal Description
Interaction-ID: 37523

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

NDUFV2

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for NDUFV2
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'oxidative phosphorylation' (OXPHOS), represented by 33 upregulated electron transport chain genes.
Formal Description
Interaction-ID: 37524

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

NDUFB6

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for NDUFB6
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'oxidative phosphorylation' (OXPHOS), represented by 33 upregulated electron transport chain genes.
Formal Description
Interaction-ID: 37525

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

NDUFB7

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for NDUFB7
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'oxidative phosphorylation' (OXPHOS), represented by 33 upregulated electron transport chain genes.
Formal Description
Interaction-ID: 37526

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

NDUFA1

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for NDUFA1
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'oxidative phosphorylation' (OXPHOS), represented by 33 upregulated electron transport chain genes.
Formal Description
Interaction-ID: 37527

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

NDUFA3

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for NDUFA3
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'oxidative phosphorylation' (OXPHOS), represented by 33 upregulated electron transport chain genes.
Formal Description
Interaction-ID: 37528

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

NDUFA5

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for NDUFA5
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'oxidative phosphorylation' (OXPHOS), represented by 33 upregulated electron transport chain genes.
Formal Description
Interaction-ID: 37529

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

NDUFA9

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for NDUFA9
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'oxidative phosphorylation' (OXPHOS), represented by 33 upregulated electron transport chain genes.
Formal Description
Interaction-ID: 37530

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

NDUFA10

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for NDUFA10
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'oxidative phosphorylation' (OXPHOS), represented by 33 upregulated electron transport chain genes.
Formal Description
Interaction-ID: 37531

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

NDUFAB1

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for NDUFAB1
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'oxidative phosphorylation' (OXPHOS), represented by 33 upregulated electron transport chain genes.
Formal Description
Interaction-ID: 37532

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

SDHA

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for SDHA
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'oxidative phosphorylation' (OXPHOS), represented by 33 upregulated electron transport chain genes.
Formal Description
Interaction-ID: 37533

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

SDHB

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for SDHB
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'oxidative phosphorylation' (OXPHOS), represented by 33 upregulated electron transport chain genes.
Formal Description
Interaction-ID: 37534

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

SDHC

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for SDHC
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'oxidative phosphorylation' (OXPHOS), represented by 33 upregulated electron transport chain genes.
Formal Description
Interaction-ID: 37535

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

SDHD

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for SDHD
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'oxidative phosphorylation' (OXPHOS), represented by 33 upregulated electron transport chain genes.
Formal Description
Interaction-ID: 37536

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

ETFA

in adipose tissue; in obese Zucker rats
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'oxidative phosphorylation' (OXPHOS), represented by 33 upregulated electron transport chain genes.
Formal Description
Interaction-ID: 37537

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

UQCRFS1

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for UQCRFS1
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'oxidative phosphorylation' (OXPHOS), represented by 33 upregulated electron transport chain genes.
Formal Description
Interaction-ID: 37538

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

CYC1

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for CYC1
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'oxidative phosphorylation' (OXPHOS), represented by 33 upregulated electron transport chain genes.
Formal Description
Interaction-ID: 37539

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

UQCRC2

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for UQCRC2
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'oxidative phosphorylation' (OXPHOS), represented by 33 upregulated electron transport chain genes.
Formal Description
Interaction-ID: 37540

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

UQCRH

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for UQCRH
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'oxidative phosphorylation' (OXPHOS), represented by 33 upregulated electron transport chain genes.
Formal Description
Interaction-ID: 37541

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

UQCR10

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for UQCR10
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'oxidative phosphorylation' (OXPHOS), represented by 33 upregulated electron transport chain genes.
Formal Description
Interaction-ID: 37542

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

COX5A

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for COX5A
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'oxidative phosphorylation' (OXPHOS), represented by 33 upregulated electron transport chain genes.
Formal Description
Interaction-ID: 37543

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

COX6A1

in adipose tissue; in obese Zucker rats
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'oxidative phosphorylation' (OXPHOS), represented by 33 upregulated electron transport chain genes.
Formal Description
Interaction-ID: 37544

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

COX6B1

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for COX6B1
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'oxidative phosphorylation' (OXPHOS), represented by 33 upregulated electron transport chain genes.
Formal Description
Interaction-ID: 37545

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

COX7A1

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for COX7A1
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'oxidative phosphorylation' (OXPHOS), represented by 33 upregulated electron transport chain genes.
Formal Description
Interaction-ID: 37546

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

COX7B

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for COX7B
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'oxidative phosphorylation' (OXPHOS), represented by 33 upregulated electron transport chain genes.
Formal Description
Interaction-ID: 37547

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

ATP5F1A

in adipose tissue; in obese Zucker rats
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'oxidative phosphorylation' (OXPHOS), represented by 33 upregulated electron transport chain genes.
Formal Description
Interaction-ID: 37548

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

ATP5F1D

in adipose tissue; in obese Zucker rats
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'oxidative phosphorylation' (OXPHOS), represented by 33 upregulated electron transport chain genes.
Formal Description
Interaction-ID: 37549

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

ATP5PO

in adipose tissue; in obese Zucker rats
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'citrate cycle (TCA cycle)' represented by 25 genes.
Formal Description
Interaction-ID: 37550

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

PDHA1

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for PDHA1
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'citrate cycle (TCA cycle)' represented by 25 genes.
Formal Description
Interaction-ID: 37551

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

PDHB

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for PDHB
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'citrate cycle (TCA cycle)' represented by 25 genes.
Formal Description
Interaction-ID: 37552

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

DLD

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for DLD
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'citrate cycle (TCA cycle)' represented by 25 genes.
Formal Description
Interaction-ID: 37553

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

CS

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for CS
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'citrate cycle (TCA cycle)' represented by 25 genes.
Formal Description
Interaction-ID: 37554

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

ACO1

in adipose tissue; in obese Zucker rats
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'citrate cycle (TCA cycle)' represented by 25 genes.
Formal Description
Interaction-ID: 37555

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

ACO2

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for ACO2
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'citrate cycle (TCA cycle)' represented by 25 genes.
Formal Description
Interaction-ID: 37556

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

SUCLA2

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for SUCLA2
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'citrate cycle (TCA cycle)' represented by 25 genes.
Formal Description
Interaction-ID: 37557

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

SUCLG1

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for SUCLG1
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'citrate cycle (TCA cycle)' represented by 25 genes.
Formal Description
Interaction-ID: 37558

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

MDH2

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for MDH2
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'citrate cycle (TCA cycle)' represented by 25 genes.
Formal Description
Interaction-ID: 37559

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

PC

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for PC
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'valine, leucine, isoleucine degradation' (BCAA degradation), represented by 22 genes.
Formal Description
Interaction-ID: 37560

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

BCKDHB

in adipose tissue; in obese Zucker rats
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'valine, leucine, isoleucine degradation' (BCAA degradation), represented by 22 genes.
Formal Description
Interaction-ID: 37561

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

DBT

in adipose tissue; in obese Zucker rats
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'valine, leucine, isoleucine degradation' (BCAA degradation), represented by 22 genes.
Formal Description
Interaction-ID: 37562

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

ACADS

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for ACADS
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'valine, leucine, isoleucine degradation' (BCAA degradation), represented by 22 genes.
Formal Description
Interaction-ID: 37563

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

ACADSB

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for ACADSB
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'valine, leucine, isoleucine degradation' (BCAA degradation), represented by 22 genes.
Formal Description
Interaction-ID: 37564

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

ACADM

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for ACADM
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'valine, leucine, isoleucine degradation' (BCAA degradation), represented by 22 genes.
Formal Description
Interaction-ID: 37565

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

HADHA

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for HADHA
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'valine, leucine, isoleucine degradation' (BCAA degradation), represented by 22 genes.
Formal Description
Interaction-ID: 37566

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

ECHS1

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for ECHS1
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'valine, leucine, isoleucine degradation' (BCAA degradation), represented by 22 genes.
Formal Description
Interaction-ID: 37567

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

EHHADH

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for EHHADH
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'valine, leucine, isoleucine degradation' (BCAA degradation), represented by 22 genes.
Formal Description
Interaction-ID: 37568

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

HIBCH

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for HIBCH
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'valine, leucine, isoleucine degradation' (BCAA degradation), represented by 22 genes.
Formal Description
Interaction-ID: 37569

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

HSD17B4

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for HSD17B4
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'valine, leucine, isoleucine degradation' (BCAA degradation), represented by 22 genes.
Formal Description
Interaction-ID: 37570

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

ACAA2

in adipose tissue; in obese Zucker rats
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'valine, leucine, isoleucine degradation' (BCAA degradation), represented by 22 genes.
Formal Description
Interaction-ID: 37571

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

HADHB

in adipose tissue; in obese Zucker rats
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'valine, leucine, isoleucine degradation' (BCAA degradation), represented by 22 genes.
Formal Description
Interaction-ID: 37572

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

PCCA

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for PCCA
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'valine, leucine, isoleucine degradation' (BCAA degradation), represented by 22 genes.
Formal Description
Interaction-ID: 37573

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

MCEE

in adipose tissue; in obese Zucker rats
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'valine, leucine, isoleucine degradation' (BCAA degradation), represented by 22 genes.
Formal Description
Interaction-ID: 37574

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

ACAT1

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for ACAT1
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'valine, leucine, isoleucine degradation' (BCAA degradation), represented by 22 genes.
Formal Description
Interaction-ID: 37575

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

ACAT2

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for ACAT2
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'valine, leucine, isoleucine degradation' (BCAA degradation), represented by 22 genes.
Formal Description
Interaction-ID: 37576

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

HMGCS1

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for HMGCS1
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'valine, leucine, isoleucine degradation' (BCAA degradation), represented by 22 genes.
Formal Description
Interaction-ID: 37577

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

ALDH6A1

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for ALDH6A1
Comment PPARgamma ligand treatments increase the expression of mitochondria-associated metabolic pathways in adipose tissue. Functional analysis of the genes differentially expressed between fatty control (FC) and PPARgamma ligand-treated rats revealed enrichment for the term 'valine, leucine, isoleucine degradation' (BCAA degradation), represented by 22 genes.
Formal Description
Interaction-ID: 37578

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

ALDH9A1

in adipose tissue; in obese Zucker rats
Drugbank entries Show/Hide entries for ALDH9A1
Comment Eighty-nine genes were differentially expressed in skeletal muscle from PPARgamma ligand-treated compared with fatty control (FC) rats. The study used functional analysis to identify muscle biochemical pathway alterations associated with PPARgamma ligand treatment. Several lipid metabolism ontology categories were enriched. All the genes annotated with lipid metabolism-related terms, as well as other related genes, were upregulated by ligand treatment (37 genes). Most of these are adipocyte-associated genes including acetyl-coenzyme A carboxylase (Acaca), a fatty acid elongase (Elovl6), fatty acid-binding proteins (Fabp4, Fabp5), hormone-sensitive lipase (Lipe), lipoprotein lipase (Lpl), and retinol-binding proteins (Rbp4, Rbp7). Pparg, highly expressed in adipocytes, was also increased (5.6-fold) after ligand treatment. Interestingly, genes overexpressed in FC vs. LC rats (Angptl4, Cd36, Fasn, and Scd1) were further overexpressed in the PPARgamma ligand-treated rats. Muscle tissue expression of adipocyte markers was induced by all the PPARgamma ligand treatments, and all the genes exhibited ligand treatment-specific modulation, except for Pparg.
Formal Description
Interaction-ID: 37584

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

ACACA

in skeletal muscle; in obese and lean Zucker rats
Drugbank entries Show/Hide entries for ACACA
Comment Eighty-nine genes were differentially expressed in skeletal muscle from PPARgamma ligand-treated compared with fatty control (FC) rats. The study used functional analysis to identify muscle biochemical pathway alterations associated with PPARgamma ligand treatment. Several lipid metabolism ontology categories were enriched. All the genes annotated with lipid metabolism-related terms, as well as other related genes, were upregulated by ligand treatment (37 genes). Most of these are adipocyte-associated genes including acetyl-coenzyme A carboxylase (Acaca), a fatty acid elongase (Elovl6), fatty acid-binding proteins (Fabp4, Fabp5), hormone-sensitive lipase (Lipe), lipoprotein lipase (Lpl), and retinol-binding proteins (Rbp4, Rbp7). Pparg, highly expressed in adipocytes, was also increased (5.6-fold) after ligand treatment. Interestingly, genes overexpressed in FC vs. LC rats (Angptl4, Cd36, Fasn, and Scd1) were further overexpressed in the PPARgamma ligand-treated rats. Muscle tissue expression of adipocyte markers was induced by all the PPARgamma ligand treatments, and all the genes exhibited ligand treatment-specific modulation, except for Pparg.
Formal Description
Interaction-ID: 37586

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

ELOVL6

in skeletal muscle; in obese and lean Zucker rats
Comment Eighty-nine genes were differentially expressed in skeletal muscle from PPARgamma ligand-treated compared with fatty control (FC) rats. The study used functional analysis to identify muscle biochemical pathway alterations associated with PPARgamma ligand treatment. Several lipid metabolism ontology categories were enriched. All the genes annotated with lipid metabolism-related terms, as well as other related genes, were upregulated by ligand treatment (37 genes). Most of these are adipocyte-associated genes including acetyl-coenzyme A carboxylase (Acaca), a fatty acid elongase (Elovl6), fatty acid-binding proteins (Fabp4, Fabp5), hormone-sensitive lipase (Lipe), lipoprotein lipase (Lpl), and retinol-binding proteins (Rbp4, Rbp7). Pparg, highly expressed in adipocytes, was also increased (5.6-fold) after ligand treatment. Interestingly, genes overexpressed in FC vs. LC rats (Angptl4, Cd36, Fasn, and Scd1) were further overexpressed in the PPARgamma ligand-treated rats. Muscle tissue expression of adipocyte markers was induced by all the PPARgamma ligand treatments, and all the genes exhibited ligand treatment-specific modulation, except for Pparg.
Formal Description
Interaction-ID: 37587

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

FABP4

in skeletal muscle; in obese and lean Zucker rats
Comment Eighty-nine genes were differentially expressed in skeletal muscle from PPARgamma ligand-treated compared with fatty control (FC) rats. The study used functional analysis to identify muscle biochemical pathway alterations associated with PPARgamma ligand treatment. Several lipid metabolism ontology categories were enriched. All the genes annotated with lipid metabolism-related terms, as well as other related genes, were upregulated by ligand treatment (37 genes). Most of these are adipocyte-associated genes including acetyl-coenzyme A carboxylase (Acaca), a fatty acid elongase (Elovl6), fatty acid-binding proteins (Fabp4, Fabp5), hormone-sensitive lipase (Lipe), lipoprotein lipase (Lpl), and retinol-binding proteins (Rbp4, Rbp7). Pparg, highly expressed in adipocytes, was also increased (5.6-fold) after ligand treatment. Interestingly, genes overexpressed in FC vs. LC rats (Angptl4, Cd36, Fasn, and Scd1) were further overexpressed in the PPARgamma ligand-treated rats. Muscle tissue expression of adipocyte markers was induced by all the PPARgamma ligand treatments, and all the genes exhibited ligand treatment-specific modulation, except for Pparg.
Formal Description
Interaction-ID: 37588

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

FABP5

in skeletal muscle; in obese and lean Zucker rats
Comment Eighty-nine genes were differentially expressed in skeletal muscle from PPARgamma ligand-treated compared with fatty control (FC) rats. The study used functional analysis to identify muscle biochemical pathway alterations associated with PPARgamma ligand treatment. Several lipid metabolism ontology categories were enriched. All the genes annotated with lipid metabolism-related terms, as well as other related genes, were upregulated by ligand treatment (37 genes). Most of these are adipocyte-associated genes including acetyl-coenzyme A carboxylase (Acaca), a fatty acid elongase (Elovl6), fatty acid-binding proteins (Fabp4, Fabp5), hormone-sensitive lipase (Lipe), lipoprotein lipase (Lpl), and retinol-binding proteins (Rbp4, Rbp7). Pparg, highly expressed in adipocytes, was also increased (5.6-fold) after ligand treatment. Interestingly, genes overexpressed in FC vs. LC rats (Angptl4, Cd36, Fasn, and Scd1) were further overexpressed in the PPARgamma ligand-treated rats. Muscle tissue expression of adipocyte markers was induced by all the PPARgamma ligand treatments, and all the genes exhibited ligand treatment-specific modulation, except for Pparg.
Formal Description
Interaction-ID: 37589

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

LIPE

in skeletal muscle; in obese and lean Zucker rats
Comment Eighty-nine genes were differentially expressed in skeletal muscle from PPARgamma ligand-treated compared with fatty control (FC) rats. The study used functional analysis to identify muscle biochemical pathway alterations associated with PPARgamma ligand treatment. Several lipid metabolism ontology categories were enriched. All the genes annotated with lipid metabolism-related terms, as well as other related genes, were upregulated by ligand treatment (37 genes). Most of these are adipocyte-associated genes including acetyl-coenzyme A carboxylase (Acaca), a fatty acid elongase (Elovl6), fatty acid-binding proteins (Fabp4, Fabp5), hormone-sensitive lipase (Lipe), lipoprotein lipase (Lpl), and retinol-binding proteins (Rbp4, Rbp7). Pparg, highly expressed in adipocytes, was also increased (5.6-fold) after ligand treatment. Interestingly, genes overexpressed in FC vs. LC rats (Angptl4, Cd36, Fasn, and Scd1) were further overexpressed in the PPARgamma ligand-treated rats. Muscle tissue expression of adipocyte markers was induced by all the PPARgamma ligand treatments, and all the genes exhibited ligand treatment-specific modulation, except for Pparg.
Formal Description
Interaction-ID: 37590

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

LPL

in skeletal muscle; in obese and lean Zucker rats
Drugbank entries Show/Hide entries for LPL
Comment Eighty-nine genes were differentially expressed in skeletal muscle from PPARgamma ligand-treated compared with fatty control (FC) rats. The study used functional analysis to identify muscle biochemical pathway alterations associated with PPARgamma ligand treatment. Several lipid metabolism ontology categories were enriched. All the genes annotated with lipid metabolism-related terms, as well as other related genes, were upregulated by ligand treatment (37 genes). Most of these are adipocyte-associated genes including acetyl-coenzyme A carboxylase (Acaca), a fatty acid elongase (Elovl6), fatty acid-binding proteins (Fabp4, Fabp5), hormone-sensitive lipase (Lipe), lipoprotein lipase (Lpl), and retinol-binding proteins (Rbp4, Rbp7). Pparg, highly expressed in adipocytes, was also increased (5.6-fold) after ligand treatment. Interestingly, genes overexpressed in FC vs. LC rats (Angptl4, Cd36, Fasn, and Scd1) were further overexpressed in the PPARgamma ligand-treated rats. Muscle tissue expression of adipocyte markers was induced by all the PPARgamma ligand treatments, and all the genes exhibited ligand treatment-specific modulation, except for Pparg.
Formal Description
Interaction-ID: 37591

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

RBP4

in skeletal muscle; in obese and lean Zucker rats
Comment Eighty-nine genes were differentially expressed in skeletal muscle from PPARgamma ligand-treated compared with fatty control (FC) rats. The study used functional analysis to identify muscle biochemical pathway alterations associated with PPARgamma ligand treatment. Several lipid metabolism ontology categories were enriched. All the genes annotated with lipid metabolism-related terms, as well as other related genes, were upregulated by ligand treatment (37 genes). Most of these are adipocyte-associated genes including acetyl-coenzyme A carboxylase (Acaca), a fatty acid elongase (Elovl6), fatty acid-binding proteins (Fabp4, Fabp5), hormone-sensitive lipase (Lipe), lipoprotein lipase (Lpl), and retinol-binding proteins (Rbp4, Rbp7). Pparg, highly expressed in adipocytes, was also increased (5.6-fold) after ligand treatment. Interestingly, genes overexpressed in FC vs. LC rats (Angptl4, Cd36, Fasn, and Scd1) were further overexpressed in the PPARgamma ligand-treated rats. Muscle tissue expression of adipocyte markers was induced by all the PPARgamma ligand treatments, and all the genes exhibited ligand treatment-specific modulation, except for Pparg.
Formal Description
Interaction-ID: 37592

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

RBP7

in skeletal muscle; in obese and lean Zucker rats
Comment Eighty-nine genes were differentially expressed in skeletal muscle from PPARgamma ligand-treated compared with fatty control (FC) rats. The study used functional analysis to identify muscle biochemical pathway alterations associated with PPARgamma ligand treatment. Several lipid metabolism ontology categories were enriched. All the genes annotated with lipid metabolism-related terms, as well as other related genes, were upregulated by ligand treatment (37 genes). Most of these are adipocyte-associated genes including acetyl-coenzyme A carboxylase (Acaca), a fatty acid elongase (Elovl6), fatty acid-binding proteins (Fabp4, Fabp5), hormone-sensitive lipase (Lipe), lipoprotein lipase (Lpl), and retinol-binding proteins (Rbp4, Rbp7). Pparg, highly expressed in adipocytes, was also increased (5.6-fold) after ligand treatment. Interestingly, genes overexpressed in FC vs. LC rats (Angptl4, Cd36, Fasn, and Scd1) were further overexpressed in the PPARgamma ligand-treated rats. Muscle tissue expression of adipocyte markers was induced by all the PPARgamma ligand treatments, and all the genes exhibited ligand treatment-specific modulation, except for Pparg.
Formal Description
Interaction-ID: 37593

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

PPARG

in skeletal muscle; in obese and lean Zucker rats
Drugbank entries Show/Hide entries for PPARG
Comment Eighty-nine genes were differentially expressed in skeletal muscle from PPARgamma ligand-treated compared with fatty control (FC) rats. The study used functional analysis to identify muscle biochemical pathway alterations associated with PPARgamma ligand treatment. Several lipid metabolism ontology categories were enriched. All the genes annotated with lipid metabolism-related terms, as well as other related genes, were upregulated by ligand treatment (37 genes). Most of these are adipocyte-associated genes including acetyl-coenzyme A carboxylase (Acaca), a fatty acid elongase (Elovl6), fatty acid-binding proteins (Fabp4, Fabp5), hormone-sensitive lipase (Lipe), lipoprotein lipase (Lpl), and retinol-binding proteins (Rbp4, Rbp7). Pparg, highly expressed in adipocytes, was also increased (5.6-fold) after ligand treatment. Interestingly, genes overexpressed in FC vs. LC rats (Angptl4, Cd36, Fasn, and Scd1) were further overexpressed in the PPARgamma ligand-treated rats. Muscle tissue expression of adipocyte markers was induced by all the PPARgamma ligand treatments, and all the genes exhibited ligand treatment-specific modulation, except for Pparg.
Formal Description
Interaction-ID: 37594

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

ANGPTL4

in skeletal muscle; in obese and lean Zucker rats
Comment Eighty-nine genes were differentially expressed in skeletal muscle from PPARgamma ligand-treated compared with fatty control (FC) rats. The study used functional analysis to identify muscle biochemical pathway alterations associated with PPARgamma ligand treatment. Several lipid metabolism ontology categories were enriched. All the genes annotated with lipid metabolism-related terms, as well as other related genes, were upregulated by ligand treatment (37 genes). Most of these are adipocyte-associated genes including acetyl-coenzyme A carboxylase (Acaca), a fatty acid elongase (Elovl6), fatty acid-binding proteins (Fabp4, Fabp5), hormone-sensitive lipase (Lipe), lipoprotein lipase (Lpl), and retinol-binding proteins (Rbp4, Rbp7). Pparg, highly expressed in adipocytes, was also increased (5.6-fold) after ligand treatment. Interestingly, genes overexpressed in FC vs. LC rats (Angptl4, Cd36, Fasn, and Scd1) were further overexpressed in the PPARgamma ligand-treated rats. Muscle tissue expression of adipocyte markers was induced by all the PPARgamma ligand treatments, and all the genes exhibited ligand treatment-specific modulation, except for Pparg.
Formal Description
Interaction-ID: 37595

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

CD36

in skeletal muscle; in obese and lean Zucker rats
Comment Eighty-nine genes were differentially expressed in skeletal muscle from PPARgamma ligand-treated compared with fatty control (FC) rats. The study used functional analysis to identify muscle biochemical pathway alterations associated with PPARgamma ligand treatment. Several lipid metabolism ontology categories were enriched. All the genes annotated with lipid metabolism-related terms, as well as other related genes, were upregulated by ligand treatment (37 genes). Most of these are adipocyte-associated genes including acetyl-coenzyme A carboxylase (Acaca), a fatty acid elongase (Elovl6), fatty acid-binding proteins (Fabp4, Fabp5), hormone-sensitive lipase (Lipe), lipoprotein lipase (Lpl), and retinol-binding proteins (Rbp4, Rbp7). Pparg, highly expressed in adipocytes, was also increased (5.6-fold) after ligand treatment. Interestingly, genes overexpressed in FC vs. LC rats (Angptl4, Cd36, Fasn, and Scd1) were further overexpressed in the PPARgamma ligand-treated rats. Muscle tissue expression of adipocyte markers was induced by all the PPARgamma ligand treatments, and all the genes exhibited ligand treatment-specific modulation, except for Pparg.
Formal Description
Interaction-ID: 37596

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

FASN

in skeletal muscle; in obese and lean Zucker rats
Drugbank entries Show/Hide entries for FASN
Comment Eighty-nine genes were differentially expressed in skeletal muscle from PPARgamma ligand-treated compared with fatty control (FC) rats. The study used functional analysis to identify muscle biochemical pathway alterations associated with PPARgamma ligand treatment. Several lipid metabolism ontology categories were enriched. All the genes annotated with lipid metabolism-related terms, as well as other related genes, were upregulated by ligand treatment (37 genes). Most of these are adipocyte-associated genes including acetyl-coenzyme A carboxylase (Acaca), a fatty acid elongase (Elovl6), fatty acid-binding proteins (Fabp4, Fabp5), hormone-sensitive lipase (Lipe), lipoprotein lipase (Lpl), and retinol-binding proteins (Rbp4, Rbp7). Pparg, highly expressed in adipocytes, was also increased (5.6-fold) after ligand treatment. Interestingly, genes overexpressed in FC vs. LC rats (Angptl4, Cd36, Fasn, and Scd1) were further overexpressed in the PPARgamma ligand-treated rats. Muscle tissue expression of adipocyte markers was induced by all the PPARgamma ligand treatments, and all the genes exhibited ligand treatment-specific modulation, except for Pparg.
Formal Description
Interaction-ID: 37597

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

SCD

in skeletal muscle; in obese and lean Zucker rats
Comment The PPARgamma ligand treatments also induced expression of slow-twitch muscle fiber markers in skeletal muscle profiles, including the three troponin subunits specific for slow-twitch skeletal muscle (Tnnc1, Tnni1, Tnnt1) and the slow-twitch type I fiber type-specific myosin heavy-chain 7 (Myh7). Two genes involved in calcium transport and binding in the sarcoplasmic reticulum of slow-twitch fiber types (Atp2a2, Casq2) were also upregulated after PPARgamma ligand treatment. The slow-twitch muscle markers tended to be overexpressed in the fatty control (FC) vs. lean control (LC) rats, but this did not exceed the stringent significance thresholds. Tnnc1 and Tnni1 exhibited ligand treatment-selective modulation, which was not correlated with ligand treatment insulin-sensitizing potency. Overall, the observations in skeletal muscle profiles suggest that insulin resistance is associated with moderate remodeling of the skeletal muscle, involving increased adiposity and slow-twitch muscle fibers, and that this remodeling is further amplified after PPARgamma ligand treatment.
Formal Description
Interaction-ID: 37598

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

TNNC1

in skeletal muscle
Drugbank entries Show/Hide entries for TNNC1
Comment The PPARgamma ligand treatments also induced expression of slow-twitch muscle fiber markers in skeletal muscle profiles, including the three troponin subunits specific for slow-twitch skeletal muscle (Tnnc1, Tnni1, Tnnt1) and the slow-twitch type I fiber type-specific myosin heavy-chain 7 (Myh7). Two genes involved in calcium transport and binding in the sarcoplasmic reticulum of slow-twitch fiber types (Atp2a2, Casq2) were also upregulated after PPARgamma ligand treatment. The slow-twitch muscle markers tended to be overexpressed in the fatty control (FC) vs. lean control (LC) rats, but this did not exceed the stringent significance thresholds. Tnnc1 and Tnni1 exhibited ligand treatment-selective modulation, which was not correlated with ligand treatment insulin-sensitizing potency. Overall, the observations in skeletal muscle profiles suggest that insulin resistance is associated with moderate remodeling of the skeletal muscle, involving increased adiposity and slow-twitch muscle fibers, and that this remodeling is further amplified after PPARgamma ligand treatment.
Formal Description
Interaction-ID: 37599

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

TNNI1

in skeletal muscle
Comment The PPARgamma ligand treatments also induced expression of slow-twitch muscle fiber markers in skeletal muscle profiles, including the three troponin subunits specific for slow-twitch skeletal muscle (Tnnc1, Tnni1, Tnnt1) and the slow-twitch type I fiber type-specific myosin heavy-chain 7 (Myh7). Two genes involved in calcium transport and binding in the sarcoplasmic reticulum of slow-twitch fiber types (Atp2a2, Casq2) were also upregulated after PPARgamma ligand treatment. The slow-twitch muscle markers tended to be overexpressed in the fatty control (FC) vs. lean control (LC) rats, but this did not exceed the stringent significance thresholds. Tnnc1 and Tnni1 exhibited ligand treatment-selective modulation, which was not correlated with ligand treatment insulin-sensitizing potency. Overall, the observations in skeletal muscle profiles suggest that insulin resistance is associated with moderate remodeling of the skeletal muscle, involving increased adiposity and slow-twitch muscle fibers, and that this remodeling is further amplified after PPARgamma ligand treatment.
Formal Description
Interaction-ID: 37600

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

TNNT1

in skeletal muscle
Comment The PPARgamma ligand treatments also induced expression of slow-twitch muscle fiber markers in skeletal muscle profiles, including the three troponin subunits specific for slow-twitch skeletal muscle (Tnnc1, Tnni1, Tnnt1) and the slow-twitch type I fiber type-specific myosin heavy-chain 7 (Myh7). Two genes involved in calcium transport and binding in the sarcoplasmic reticulum of slow-twitch fiber types (Atp2a2, Casq2) were also upregulated after PPARgamma ligand treatment. The slow-twitch muscle markers tended to be overexpressed in the fatty control (FC) vs. lean control (LC) rats, but this did not exceed the stringent significance thresholds. Tnnc1 and Tnni1 exhibited ligand treatment-selective modulation, which was not correlated with ligand treatment insulin-sensitizing potency. Overall, the observations in skeletal muscle profiles suggest that insulin resistance is associated with moderate remodeling of the skeletal muscle, involving increased adiposity and slow-twitch muscle fibers, and that this remodeling is further amplified after PPARgamma ligand treatment.
Formal Description
Interaction-ID: 37601

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

MYH7

in skeletal muscle
Drugbank entries Show/Hide entries for MYH7
Comment The PPARgamma ligand treatments also induced expression of slow-twitch muscle fiber markers in skeletal muscle profiles, including the three troponin subunits specific for slow-twitch skeletal muscle (Tnnc1, Tnni1, Tnnt1) and the slow-twitch type I fiber type-specific myosin heavy-chain 7 (Myh7). Two genes involved in calcium transport and binding in the sarcoplasmic reticulum of slow-twitch fiber types (Atp2a2, Casq2) were also upregulated after PPARgamma ligand treatment. The slow-twitch muscle markers tended to be overexpressed in the fatty control (FC) vs. lean control (LC) rats, but this did not exceed the stringent significance thresholds. Tnnc1 and Tnni1 exhibited ligand treatment-selective modulation, which was not correlated with ligand treatment insulin-sensitizing potency. Overall, the observations in skeletal muscle profiles suggest that insulin resistance is associated with moderate remodeling of the skeletal muscle, involving increased adiposity and slow-twitch muscle fibers, and that this remodeling is further amplified after PPARgamma ligand treatment.
Formal Description
Interaction-ID: 37602

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

ATP2A2

in skeletal muscle
Comment The PPARgamma ligand treatments also induced expression of slow-twitch muscle fiber markers in skeletal muscle profiles, including the three troponin subunits specific for slow-twitch skeletal muscle (Tnnc1, Tnni1, Tnnt1) and the slow-twitch type I fiber type-specific myosin heavy-chain 7 (Myh7). Two genes involved in calcium transport and binding in the sarcoplasmic reticulum of slow-twitch fiber types (Atp2a2, Casq2) were also upregulated after PPARgamma ligand treatment. The slow-twitch muscle markers tended to be overexpressed in the fatty control (FC) vs. lean control (LC) rats, but this did not exceed the stringent significance thresholds. Tnnc1 and Tnni1 exhibited ligand treatment-selective modulation, which was not correlated with ligand treatment insulin-sensitizing potency. Overall, the observations in skeletal muscle profiles suggest that insulin resistance is associated with moderate remodeling of the skeletal muscle, involving increased adiposity and slow-twitch muscle fibers, and that this remodeling is further amplified after PPARgamma ligand treatment.
Formal Description
Interaction-ID: 37603

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

CASQ2

in skeletal muscle
Comment The PPARgamma ligand treatments also induced expression of slow-twitch muscle fiber markers in skeletal muscle profiles, including the three troponin subunits specific for slow-twitch skeletal muscle (Tnnc1, Tnni1, Tnnt1) and the slow-twitch type I fiber type-specific myosin heavy-chain 7 (Myh7). Two genes involved in calcium transport and binding in the sarcoplasmic reticulum of slow-twitch fiber types (Atp2a2, Casq2) were also upregulated after PPARgamma ligand treatment. The slow-twitch muscle markers tended to be overexpressed in the fatty control (FC) vs. lean control (LC) rats, but this did not exceed the stringent significance thresholds. Tnnc1 and Tnni1 exhibited ligand treatment-selective modulation, which was not correlated with ligand treatment insulin-sensitizing potency. Overall, the observations in skeletal muscle profiles suggest that insulin resistance is associated with moderate remodeling of the skeletal muscle, involving increased adiposity and slow-twitch muscle fibers, and that this remodeling is further amplified after PPARgamma ligand treatment.
Formal Description
Interaction-ID: 37604

drug/chemical compound

Thiazolidinedione

affects_activity of

in skeletal muscle
Comment Srebf1 expression in PPARgamma ligand-treated fatty rats was normalized down to lean control (LC) levels and was not different between the ligand treatment groups. Expression of several Srebf1 target genes associated with lipogenesis was also decreased by at least one of the ligand treatments (Elovl5, Fasn, G6pdx, Me1, Scd1). Of these, G6pdx expression was completely normalized to LC levels. Ligand treatment increased pyruvate dehydrogenase kinase-4 (Pdk4) expression. In its active state, PDK4 protein inhibits pyruvate dehydrogenase complex conversion of pyruvate into acetyl-CoA, effectively preventing the accumulation of the fatty acid precursors. Blunted cholesterol synthesis gene expression in FC rats was increased by PPARgamma ligand treatment (Cyp51, Idi1, Sc4mol, Sqle) with Cyp51, Sc4mol, and Sqle expression normalized to LC levels.
Formal Description
Interaction-ID: 37618

drug/chemical compound

Thiazolidinedione

decreases_expression of

gene/protein

SREBF1

in liver; in obese Zucker rats
Comment Srebf1 expression in PPARgamma ligand-treated fatty rats was normalized down to lean control (LC) levels and was not different between the ligand treatment groups. Expression of several Srebf1 target genes associated with lipogenesis was also decreased by at least one of the ligand treatments (Elovl5, Fasn, G6pdx, Me1, Scd1). Of these, G6pdx expression was completely normalized to LC levels. Ligand treatment increased pyruvate dehydrogenase kinase-4 (Pdk4) expression. In its active state, PDK4 protein inhibits pyruvate dehydrogenase complex conversion of pyruvate into acetyl-CoA, effectively preventing the accumulation of the fatty acid precursors. Blunted cholesterol synthesis gene expression in FC rats was increased by PPARgamma ligand treatment (Cyp51, Idi1, Sc4mol, Sqle) with Cyp51, Sc4mol, and Sqle expression normalized to LC levels.
Formal Description
Interaction-ID: 37619

drug/chemical compound

Thiazolidinedione

decreases_expression of

gene/protein

ELOVL5

in liver; in obese Zucker rats
Comment Srebf1 expression in PPARgamma ligand-treated fatty rats was normalized down to lean control (LC) levels and was not different between the ligand treatment groups. Expression of several Srebf1 target genes associated with lipogenesis was also decreased by at least one of the ligand treatments (Elovl5, Fasn, G6pdx, Me1, Scd1). Of these, G6pdx expression was completely normalized to LC levels. Ligand treatment increased pyruvate dehydrogenase kinase-4 (Pdk4) expression. In its active state, PDK4 protein inhibits pyruvate dehydrogenase complex conversion of pyruvate into acetyl-CoA, effectively preventing the accumulation of the fatty acid precursors. Blunted cholesterol synthesis gene expression in FC rats was increased by PPARgamma ligand treatment (Cyp51, Idi1, Sc4mol, Sqle) with Cyp51, Sc4mol, and Sqle expression normalized to LC levels.
Formal Description
Interaction-ID: 37620

drug/chemical compound

Thiazolidinedione

decreases_expression of

gene/protein

FASN

in liver; in obese Zucker rats
Drugbank entries Show/Hide entries for FASN
Comment Srebf1 expression in PPARgamma ligand-treated fatty rats was normalized down to lean control (LC) levels and was not different between the ligand treatment groups. Expression of several Srebf1 target genes associated with lipogenesis was also decreased by at least one of the ligand treatments (Elovl5, Fasn, G6pdx, Me1, Scd1). Of these, G6pdx expression was completely normalized to LC levels. Ligand treatment increased pyruvate dehydrogenase kinase-4 (Pdk4) expression. In its active state, PDK4 protein inhibits pyruvate dehydrogenase complex conversion of pyruvate into acetyl-CoA, effectively preventing the accumulation of the fatty acid precursors. Blunted cholesterol synthesis gene expression in FC rats was increased by PPARgamma ligand treatment (Cyp51, Idi1, Sc4mol, Sqle) with Cyp51, Sc4mol, and Sqle expression normalized to LC levels.
Formal Description
Interaction-ID: 37621

drug/chemical compound

Thiazolidinedione

decreases_expression of

gene/protein

G6PD

in liver; in obese Zucker rats
Drugbank entries Show/Hide entries for G6PD
Comment Srebf1 expression in PPARgamma ligand-treated fatty rats was normalized down to lean control (LC) levels and was not different between the ligand treatment groups. Expression of several Srebf1 target genes associated with lipogenesis was also decreased by at least one of the ligand treatments (Elovl5, Fasn, G6pdx, Me1, Scd1). Of these, G6pdx expression was completely normalized to LC levels. Ligand treatment increased pyruvate dehydrogenase kinase-4 (Pdk4) expression. In its active state, PDK4 protein inhibits pyruvate dehydrogenase complex conversion of pyruvate into acetyl-CoA, effectively preventing the accumulation of the fatty acid precursors. Blunted cholesterol synthesis gene expression in FC rats was increased by PPARgamma ligand treatment (Cyp51, Idi1, Sc4mol, Sqle) with Cyp51, Sc4mol, and Sqle expression normalized to LC levels.
Formal Description
Interaction-ID: 37622

drug/chemical compound

Thiazolidinedione

decreases_expression of

gene/protein

ME1

in liver; in obese Zucker rats
Drugbank entries Show/Hide entries for ME1
Comment Srebf1 expression in PPARgamma ligand-treated fatty rats was normalized down to lean control (LC) levels and was not different between the ligand treatment groups. Expression of several Srebf1 target genes associated with lipogenesis was also decreased by at least one of the ligand treatments (Elovl5, Fasn, G6pdx, Me1, Scd1). Of these, G6pdx expression was completely normalized to LC levels. Ligand treatment increased pyruvate dehydrogenase kinase-4 (Pdk4) expression. In its active state, PDK4 protein inhibits pyruvate dehydrogenase complex conversion of pyruvate into acetyl-CoA, effectively preventing the accumulation of the fatty acid precursors. Blunted cholesterol synthesis gene expression in FC rats was increased by PPARgamma ligand treatment (Cyp51, Idi1, Sc4mol, Sqle) with Cyp51, Sc4mol, and Sqle expression normalized to LC levels.
Formal Description
Interaction-ID: 37623

drug/chemical compound

Thiazolidinedione

decreases_expression of

gene/protein

SCD

in liver; in obese Zucker rats
Comment Srebf1 expression in PPARgamma ligand-treated fatty rats was normalized down to lean control (LC) levels and was not different between the ligand treatment groups. Expression of several Srebf1 target genes associated with lipogenesis was also decreased by at least one of the ligand treatments (Elovl5, Fasn, G6pdx, Me1, Scd1). Of these, G6pdx expression was completely normalized to LC levels. Ligand treatment increased pyruvate dehydrogenase kinase-4 (Pdk4) expression. In its active state, PDK4 protein inhibits pyruvate dehydrogenase complex conversion of pyruvate into acetyl-CoA, effectively preventing the accumulation of the fatty acid precursors. Blunted cholesterol synthesis gene expression in FC rats was increased by PPARgamma ligand treatment (Cyp51, Idi1, Sc4mol, Sqle) with Cyp51, Sc4mol, and Sqle expression normalized to LC levels.
Formal Description
Interaction-ID: 37624

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

PDK4

in liver; in obese Zucker rats
Drugbank entries Show/Hide entries for PDK4
Comment Srebf1 expression in PPARgamma ligand-treated fatty rats was normalized down to lean control (LC) levels and was not different between the ligand treatment groups. Expression of several Srebf1 target genes associated with lipogenesis was also decreased by at least one of the ligand treatments (Elovl5, Fasn, G6pdx, Me1, Scd1). Of these, G6pdx expression was completely normalized to LC levels. Ligand treatment increased pyruvate dehydrogenase kinase-4 (Pdk4) expression. In its active state, PDK4 protein inhibits pyruvate dehydrogenase complex conversion of pyruvate into acetyl-CoA, effectively preventing the accumulation of the fatty acid precursors. Blunted cholesterol synthesis gene expression in FC rats was increased by PPARgamma ligand treatment (Cyp51, Idi1, Sc4mol, Sqle) with Cyp51, Sc4mol, and Sqle expression normalized to LC levels.
Formal Description
Interaction-ID: 37625

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

CYP51A1

in liver; in obese Zucker rats
Drugbank entries Show/Hide entries for CYP51A1
Comment Srebf1 expression in PPARgamma ligand-treated fatty rats was normalized down to lean control (LC) levels and was not different between the ligand treatment groups. Expression of several Srebf1 target genes associated with lipogenesis was also decreased by at least one of the ligand treatments (Elovl5, Fasn, G6pdx, Me1, Scd1). Of these, G6pdx expression was completely normalized to LC levels. Ligand treatment increased pyruvate dehydrogenase kinase-4 (Pdk4) expression. In its active state, PDK4 protein inhibits pyruvate dehydrogenase complex conversion of pyruvate into acetyl-CoA, effectively preventing the accumulation of the fatty acid precursors. Blunted cholesterol synthesis gene expression in FC rats was increased by PPARgamma ligand treatment (Cyp51, Idi1, Sc4mol, Sqle) with Cyp51, Sc4mol, and Sqle expression normalized to LC levels.
Formal Description
Interaction-ID: 37626

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

IDI1

in liver; in obese Zucker rats
Drugbank entries Show/Hide entries for IDI1
Comment Srebf1 expression in PPARgamma ligand-treated fatty rats was normalized down to lean control (LC) levels and was not different between the ligand treatment groups. Expression of several Srebf1 target genes associated with lipogenesis was also decreased by at least one of the ligand treatments (Elovl5, Fasn, G6pdx, Me1, Scd1). Of these, G6pdx expression was completely normalized to LC levels. Ligand treatment increased pyruvate dehydrogenase kinase-4 (Pdk4) expression. In its active state, PDK4 protein inhibits pyruvate dehydrogenase complex conversion of pyruvate into acetyl-CoA, effectively preventing the accumulation of the fatty acid precursors. Blunted cholesterol synthesis gene expression in FC rats was increased by PPARgamma ligand treatment (Cyp51, Idi1, Sc4mol, Sqle) with Cyp51, Sc4mol, and Sqle expression normalized to LC levels.
Formal Description
Interaction-ID: 37627

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

MSMO1

in liver; in obese Zucker rats
Comment Srebf1 expression in PPARgamma ligand-treated fatty rats was normalized down to lean control (LC) levels and was not different between the ligand treatment groups. Expression of several Srebf1 target genes associated with lipogenesis was also decreased by at least one of the ligand treatments (Elovl5, Fasn, G6pdx, Me1, Scd1). Of these, G6pdx expression was completely normalized to LC levels. Ligand treatment increased pyruvate dehydrogenase kinase-4 (Pdk4) expression. In its active state, PDK4 protein inhibits pyruvate dehydrogenase complex conversion of pyruvate into acetyl-CoA, effectively preventing the accumulation of the fatty acid precursors. Blunted cholesterol synthesis gene expression in FC rats was increased by PPARgamma ligand treatment (Cyp51, Idi1, Sc4mol, Sqle) with Cyp51, Sc4mol, and Sqle expression normalized to LC levels.
Formal Description
Interaction-ID: 37628

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

SQLE

in liver; in obese Zucker rats
Drugbank entries Show/Hide entries for SQLE
Comment Although PPARgamma ligand treatments heterogeneously improved dysregulated expression of cholesterol and fatty acid biosynthetic pathways in obese rat liver, these alterations were not correlated with ligand insulin-sensitizing potency.
Formal Description
Interaction-ID: 37631

drug/chemical compound

Thiazolidinedione

affects_activity of

in liver
Comment Although PPARgamma ligand treatments heterogeneously improved dysregulated expression of cholesterol and fatty acid biosynthetic pathways in obese rat liver, these alterations were not correlated with ligand insulin-sensitizing potency.
Formal Description
Interaction-ID: 37632

drug/chemical compound

Thiazolidinedione

affects_activity of

in liver
Comment PPARgamma ligand treatment-specific insulin-sensitizing potency correlated with modulation of adipose tissue inflammatory and BCAA metabolic pathways, suggesting a functional relationship between these pathways and whole body insulin sensitivity. Other PPARgamma ligand treatment-induced functional pathway changes were detected in adipose tissue, skeletal muscle, and liver profiles but were not related to degree of insulin sensitization.
Formal Description
Interaction-ID: 37633

drug/chemical compound

Thiazolidinedione

affects_activity of

in adipose tissue
Comment PPARgamma ligand treatment-specific insulin-sensitizing potency correlated with modulation of adipose tissue inflammatory and BCAA metabolic pathways, suggesting a functional relationship between these pathways and whole body insulin sensitivity. Other PPARgamma ligand treatment-induced functional pathway changes were detected in adipose tissue, skeletal muscle, and liver profiles but were not related to degree of insulin sensitization.
Formal Description
Interaction-ID: 37634

drug/chemical compound

Thiazolidinedione

affects_activity of

in adipose tissue